Jefferson City Headlines

Delveinsight Business Research LLP

DelveInsight’s “Presbyopia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Presbyopia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Presbyopia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Presbyopia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Presbyopia: An Overview

According to the American Academy of Ophthalmology, presbyopia is a normal part of aging wherein eyes gradually lose the ability to see things clearly up close. The term “presbyopia” comes from a Greek word which means “old eye.” Most people begin to notice the effect of presbyopia sometime after the age of 40 as the lenses of the eyes naturally lose their elasticity due to the aging process.

Presbyopia can be classified as incipient presbyopia, functional presbyopia, absolute presbyopia, premature presbyopia, and nocturnal presbyopia. It is mostly due to age-related changes in the proteins within the lens of the eye that cause it to become thicker, harder, and less flexible. This loss of flexibility affects the lens’s ability to refract light rays which, in turn, affects the eye’s capacity to focus. Age is the major risk factor for the development of presbyopia along with factors like trauma, systemic disease, cardiovascular disease, or a drug side effect.

Presbyopia Market Key Facts

• The United States accounts for the largest market size of Presbyopia, in comparison to EU5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.

• Among the EU5 countries, Germany had the highest market size with USD 1,936 million in 2021.

• Total prevalent cases of Presbyopia in the 7MM were found to be 289,136,235 cases in 2021. These cases are expected to change by 2032 at a CAGR of 1.4% during the study period (2019–2032).

• Among 7MM, the United States has the highest number of prevalent cases of Presbyopia with 118,346,762 cases in 2021.

• Assessments as per DelveInsight’s analysts show that in 2021, in the United States, the severity-specific cases of Presbyopia were 20,301,021 and 81,204,086 cases for mild and moderate to severe cases, respectively which are expected to rise significantly by 2032.

• In the US, the total age-specific cases of Presbyopia were 28,859,295, 33,190,032, 24,012,555, and 15,443,224 cases for the age group less than 60 years, 60–69 years, 70–79 years, and ≥80 years respectively, in the year 2021. These cases are expected to rise significantly by 2032.

• In EU-5, Germany had the highest prevalent population of Presbyopia with 36,822,212 cases, followed by Italy with 27,683,651 cases in 2021. On the other hand, Spain had the lowest prevalent population for 2021.

• In 2021, Japan had 34,568,372 total prevalent cases of Presbyopia.

Presbyopia Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Presbyopia pipeline therapies. It also thoroughly assesses the Presbyopia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Presbyopia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Presbyopia Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Presbyopia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Presbyopia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Presbyopia Epidemiology, Segmented as –

• Total prevalent cases of Presbyopia

• Total diagnosed cases of Presbyopia

• Total age-specific cases of Presbyopia

• Gender-specific cases of Presbyopia

• Severity-specific cases of Presbyopia

Presbyopia Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Presbyopia market or expected to be launched during the study period. The analysis covers the Presbyopia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Presbyopia drugs based on their sale and market share.

The report also covers the Presbyopia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Presbyopia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Presbyopia Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/presbyopia-market

Presbyopia Therapeutics Analysis

The goal of treatment is to compensate for the eye’s inability to focus on nearby objects. A variety of options are available for optical correction of presbyopia. Treatment includes wearing corrective eyeglasses (spectacle lenses) or contact lenses, undergoing refractive surgery, or getting lens implants for presbyopia. Most clinical management of presbyopia includes nonsteroidal anti-inflammatory drugs (NSAIDs), parasympathetic agonists, miotic agents, or some other tempering agents. The commonly used off-label ophthalmic drops have pilocarpine, carbachol, aceclidine, brimonidine, nepafenac as their main ingredient. They target the ciliary muscles and change pupil size and elasticity, thereby improving the near vision. Recently the US FDA approved VUNITY developed by AbbVie, for the treatment of presbyopia in adults.

The Presbyopia pipeline is active with several pipeline candidates in the early and late stages of development. Several major pharma and biotech companies are developing therapies for Presbyopia. Various key assets include Orasis Pharmaceuticals (PresbiDrops), Eyenovia (MicroLine), AbbVie (AGN-241622), Ocuphire Pharma (Nyxol), Visus therapeutics (Brimochol), are under various of clinical development and hold the potential to create a significant impact on market size and treatment outlook in the near future. Currently, Orasis Pharmaceuticals is leading the therapeutics market with its Presbyopia drug candidates in the most advanced stage of clinical development.

Presbyopia Companies Actively Working in the Therapeutics Market Include

• Orasis Pharmaceuticals

• Visus Therapeutics

• Vyluma

• AbbVie

• Cellix Bio

• Eyenovia

• Glaukos Corporation

• JIXING Pharmaceuticals

• Lenz Therapeutics

• Novartis

• Ocuphire Pharma

And many others

Emerging and Marketed Presbyopia Therapies Covered in the Report Include:

• CSF-1 (PresbiDrops): Orasis Pharmaceuticals

• LNZ100 (aceclidine) & LNZ101 (aceclidine + brimonidine): Ji Xing Pharmaceuticals and LENZ Therapeutics

• MicroLine (Pilocarpine Ophthalmic): Eyenovia

• ARVN003 (Microline): Arctic Vision and Eyenovia

• Brimochol PF and Carbachol PF: Zhaoke Ophthalmology Limited and Visus Therapeutics

• Nyxol: Ocuphire Pharma

• UNR844 (Lipoic Acid Choline Ester): Novartis

• Vuity: AbbVie

And many more

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/presbyopia-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Presbyopia Competitive Intelligence Analysis

4. Presbyopia Market Overview at a Glance

5. Presbyopia Disease Background and Overview

6. Presbyopia Patient Journey

7. Presbyopia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Presbyopia Treatment Algorithm, Current Treatment, and Medical Practices

9. Presbyopia Unmet Needs

10. Key Endpoints of Presbyopia Treatment

11. Presbyopia Marketed Therapies

12. Presbyopia Emerging Drugs and Latest Therapeutic Advances

13. Presbyopia Seven Major Market Analysis

14. Attribute Analysis

15. Presbyopia Market Outlook (In US, EU5, and Japan)

16. Presbyopia Companies Active in the Market

17. Presbyopia Access and Reimbursement Overview

18. KOL Views on the Presbyopia Market

19. Presbyopia Market Drivers

20. Presbyopia Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/presbyopia-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Stargardt Disease Market

“Stargardt Disease (STGD) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Stargardt Disease market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Stargardt Disease market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology